Disposition and metabolism of the colchicine derivative [ 14C]-ZD6126 in rat and dog

Xenobiotica

Volumn 38, Issue 4, 2008, Pages 399-421

  Partridge, E A ^a   D'Souza, R A ^a   Lenz, E M ^a   Smith, S M ^a   Clarkson Jones, J ^a   Roberts, D W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

14C ZD6126; Colchicine derivative; Enterohepatic recirculation; Vascular targeting agent

Indexed keywords

N ACETYLCOLCHINOL PHOSPHATE; O DEMETHYLASE; PHENOL;

ARTICLE; CONJUGATION; DOG; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENTEROHEPATIC CIRCULATION; FEMALE; GLUCURONIDATION; MALE; NONHUMAN; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; WHOLE BODY AUTORADIOGRAPHY;

AGING; ANIMALS; BILE; CARBON RADIOISOTOPES; COLCHICINE; DOGS; FEMALE; INJECTIONS, INTRAVENOUS; MALE; ORGAN SPECIFICITY; ORGANOPHOSPHORUS COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 40749092915     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701861742     Document Type: Article

References (24)

1. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. 2002b. ZD6126: A novel small molecule vascular targeting agent. International Journal of Radiation, Oncology, Biology, Physics 54(5):1497-1502.
2. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. 2002a. Antitumour activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clinical Cancer Research 8:1974-1983.
3. Chaplin DJ, Dougherty GJ. 1999. Tumour vasculature as a target for cancer therapy. British Journal of Cancer 80(Suppl. 1):57-64.
4. 14C-ZD6126) to tumour bearing mice. Xenobiotica 37(3):328-340.
5. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, et al. 2002. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Research 62:7247-7253.
6. Gadgeel SM, LoRusso P, Morton P, Wheeler C, Barge A, Evelhoch J. 2002. MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature. Proceedings of the American Society of Clinical Oncology 21: abst 440.
7. Gibson G, Skett P. 2001. Introduction to drug metabolism (Cheltenham: Nelson Thornes).
8. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. 1999. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. British Journal of Cancer 81:1318-1827.
9. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. 1993. Vinca alkaloids: Anti-vascular effects in a murine tumour. European Journal of Cancer 29A:1320-1324.
10. Hunter AL, Klaassen CD. 1974. Biliary excretion of colchicine. Journal of Pharmacology and Experimental Therapeutics 192(3):605-617.
11. Judson I, Scurr M, Roberts DW, Partridge EA, D'Souza RA, Tan S. 2008. Pharmacokinetics and metabolism of ZD6126 in patients with solid tumours (in preparation).
12. Legraverend C, Mode A, Westin S, Strom A, Eguchi H, Zaphiropoulos PG, Gustafsson JA. 1992. Transcriptional regulation of rat P-450 2C gene subfamily members by the sexually dimorphic pattern of growth hormone secretion. Molecular Endocrinology 6:259-266.
13. 14C]-ZD6126. Journal of Pharmaceutical and Biomedical Analysis 43:1065-1077.
14. McCormick AD, Slamon DL, Lenz EM, King CD, Phillips PJ, McKillop D, Roberts DW. 2007. In vitro metabolism of M445526 (ZD6126 phenol) in human liver microsomes and hepatocytes. Xenobiotica 37(9):972-985.
15. McKillop D, Partridge EA, Hutchison M, Rhead SA, Parry AC, Bardsley J, Woodman HM, Swaisland HC. 2004. Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica 34:901-915.
16. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, Giavazzi R. 2003. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Research 63:1534-1537.
17. Radema SA, Beerepoot LV, Witteveen PO, Gebbink MF, Wheeler C, Voest EE. 2002. Clinical evaluation of the novel vascular-targeting agent, ZD6126: Assessment of toxicity and surrogate markers of vascular damage. Proceedings of the American Society of Clinical Oncology 21:abst 439.
18. Sandoval IV, Weber K. 1979. Polymerization of tubulin in the presence of colchicine or podophyllotoxin. Formation of a ribbon structure induced by guanylyl-5′-methylene diphosphonate. Journal of Molecular Biology 134:159-172.
19. Scurr M, Judson I, Brock C, O'Donnell A, Tan S, Partridge EA, D'Souza RA, Roberts D. 2004. Assessment of metabolism, excretion and pharmacokinetics of a single dose of [14C]-ZD6126 in patients with solid malignant tumours. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22 (145):3083 (abst).
20. Skett P. 1990. Role of hormones in the control of mixed function oxidases. Biochemical Society Transactions 18(1):24-26.
21. Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJJ. 1997. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochemical Pharmacology 53:111-116.
22. Tomer G, Ananthanarayanan M, Weymann A, Balasubra-manian N, Suchy FJ. 2003. Differential developmental regulation of rat liver canalicular membrane transporters Bsep and Mrp2. Pediatric Research 53(2):288-294.
23. Walaszek EJ, Kocsis JJ, Leroy GV, Geiling EMK. 1960. Studies on the excretion of radioactive colchicine. Archives Internationales de Pharmacodynamie et de Therapie 125:371-382.
24. Waxman DJ, Ram PA, Notani G, LeBlanc GA, Alberta JA, Morrissey JJ, Sundseth SS. 1990. Pituitary regulation of the male-specific steroid 6 beta-hydroxylase P-450 2a (gene product IIIA2) in adult rat liver. Suppressive influence of growth hormone and thyroxine acting at a pretranslational level. Molecular Endocrinology 4:447-454.